Methods: Selective literature review.
Results and discussion: Total serum vitamin B 12 is a late, relatively insensitive and unspecific biomarker of deficiency. Holotranscobalamin (holoTC), also known as active B 12 , is the earliest laboratory parameter for B 12 deficiency, while methyl malonic acid (MMA) is a functional B 12 marker that will increase when the B 12 stores are depleted. Isolated lowering of holoTC shows B 12 depletion (negative B 12 balance), while lowered holoTC plus elevated MMA and homocysteine indicates a metabolically manifest B 12 deficiency, although there still may be no clinical symptoms. The diagnostic use of holoTC allows treatment to be instituted before irreversible neurological damage occurs. As the first clinical manifestations of vitamin B 12 deficiency are unspecific, those at risk should have their B 12 status checked regularly, every two to three years. Because no randomized controlled trials have yet been completed, the diagnostic and therapeutic measures proposed here are merely recommendations.
M E D I C I N E
and is transferred to the intrinsic factor (IF) in the intestinal lumen by means of a pH dependent process. In the terminal ileum, the IF-B 12 complex binds to IF receptors on the membrane surface of enterocytes and is then transferred through the ileal membrane. Vitamin B 12 is subsequently released in the enterocytes and transferred to transcobalamin II (TC) (figure 1). The B 12 -TC complex-known as holotranscobalamin (holoTC)-arrives in the blood circulation and circulates until it is taken up by the cells. A maximum of 30% of circulating B 12 is bound to TC, which represents metabolically active B 12 . The vitamin B 12 that is bound to haptocorrin is thought to transport the surplus of vitamin B 12 to the liver.
Modern biomarkers for metabolic vitamin B 12 deficiency
Total vitamin B 12 measurement is used cost effectively as the parameter of choice, but it has limited sensitivity and specificity, especially in persons with vitamin B 12 concentrations <400 pmol/L (4, e4 and MMA concentrations. New data have shown that the plasma concentration of MMA and homocysteine falls when vitamin B 12 is ingested, whereas the holoTC concentration rises (9) . A minimum daily intake of 6 μg vitamin B 12 results in an optimal plasma concentration of the investigated biomarkers (9) . More recent studies have shown that the recommended daily intake of B 12 should be newly determined and seems too low, especially for older people.
Vitamin B 12 is important for DNA synthesis, and formation and maintenance of myelin sheaths, the synthesis of neurotransmitters, and erythropoiesis. Clinical vitamin B 12 deficiency has two main manifestations: hematological and neuropsychiatric disorders. Symptoms often develop before a shortfall on the lower B 12 reference limit (6) . Macrocytic anemia is regarded as a late indicator of vitamin B 12 deficiency.
The macrocytosis caused by B 12 deficiency can be masked by concomitant iron deficiency, and the diagnosis is thus difficult (e5). Iron deficiency related microcytosis dominates over B 12 deficiency related macrocytosis if the iron deficiency is more severe than the B 12 deficiency (e6). The B 12 deficiency can cause an additional loss of iron by means of a secondary effect on the enterocytes (e6).
Large vitamin B 12 stores exist in the body, which is why a deficiency will become evident only after many years. In general, vitamin B 12 deficiency develops in several stages:
> Depletion of stores > Metabolic-functional disorder > Clinical manifestation. Hyperhomocysteinemia in vitamin B 12 deficiency is important as an atherogenic risk factor but also as a sign of hypomethylation-for example, of DNA, RNA, myelin, phospholipids, or neurotransmitters. Hypomethylation occurs subsequent to the reduced availability of S-adenosyl-methionine (SAM), which is a universal methyl group donor. Vitamin B 12 deficiency inhibits methionine synthase. The result is reduced methionine synthesis, with subsequent lowering of the SAM concentration. Funicular spinal cord disease (myelosis) is a common neurological sequela of vitamin B 12 deficiency. The psychiatric and neurological disorders and the cognitive disorders, depression, or dementia that are observed in vitamin B 12 deficiency can precede hematological anomalies by years, and sometimes such anomalies do not even develop.
Morphological changes to blood and bone marrow cells are among the main symptoms of vitamin B 12 deficiency. Because of their high cell turnover rate, hematopoiesis reacts rapidly and sensitively to the blocked nucleic acid metabolism. Megaloblastic anemia in vitamin B 12 deficiency develops as a result of disrupted DNA synthesis and the resultant maturation disorder of the cell nucleus, whereas the cytoplasm develops normally. In the periphery, macrocytic erythrocytes (MCV >110 fl) and hypersegmented neutrophils can be observed.
Risk groups
The prevalence of subclinical functional vitamin B 12 deficiency is higher than hitherto assumed when sensitive and relatively specific markers are used-such as MMA, holoTC, and homocysteine (10, 11). Risk groups for vitamin B 12 deficiency include (table) > patients with unexplained anemia; > patients with unexplained neuropsychiatric symptoms; > patients with gastrointestinal manifestations, including stomatitis, anorexia, and diarrhea; > elderly people (11) ; > vegetarians (4); > patients with gastrointestinal disorders, such as Crohn's disease or infection with Helicobacter pylori, or patients with stomach resection (12) . The rate of people in the risk population who will develop clinical symptoms because of vitamin B 12 deficiency has thus far not been studied systematically. 
M E D I C I N E
In the population, the prevalence of vitamin B 12 deficiency in younger people is 5% to 7% (e7, 13). Functional vitamin B 12 deficiency-that is, raised MMA and lowered holoTC-is common in old age and has been diagnosed in 10% to 30% of patients older than 65 years of age (10, 11, 14) . A high prevalence of a slightly abnormal vitamin B 12 status has been reported in elderly people, despite intake of the recommended daily dose (> 2.4 μg/day). This deficiency is not presumed to be associated with dietary causes but with malabsorption (15) . 53% of elderly patients from Strasbourg who had vitamin B 12 deficiency had malabsorption problems, 33% had pernicious anemia; in only 2% was vitamin B 12 deficiency related to insufficient dietary intake, and in 11% the etiology of the vitamin B 12 deficiency remained unexplained (16) . However, because the currently recommended dietary intake for vitamin B 12 in elderly people is low, dietary deficiencies are underdiagnosed.
Using synthetic B 12 preparations can protect elderly persons from symptoms of deficiency (e8, 17) . Dietary intake of B 12 , however, does not provide any information on the vitamin B 12 status because malabsorption is a common and important factor. Further, elderly persons often have atrophic gastritis, pernicious anemia, or achlorhydria. Disorders that affect the gastrointestinal pH can also result in malabsorption and thus vitamin B 12 deficiency. The incidence of Helicobacter pylori is high in elderly people and can lead to atrophic gastritis, and in turn to B 12 malabsorption, owing to disrupted production of hydrochloric acid (1). Helicobacter pylori was found in 56% of patients with vitamin B 12 deficiency (18) . In 40% of patients, serum concentrations of B 12 rose after treatment for Helicobacter pylori infection. According to recent reports, longer term treatment of Helicobacter pylori (1 year) resulted in a significant rise in mean vitamin B 12 (from 146 pmol/L to 271 pmol/L) and a fall in mean homocysteine concentrations (from 41 μmol/L to 13 μmol/L) (19) . B 12 malabsorption owing to Helicobacter pylori infection can thus lead to vitamin B 12 deficiency and hyperhomocysteinemia (e9).
Vegetarians are at high risk of developing vitamin B 12 deficiency because animal products are the main sources of B 12 . A functional B 12 deficiency (lowered holoTC, raised MMA and homocysteine) is common in vegetarians and depends on the strictness of the diet and how long the vegetarian diet has been followed. A study of lacto-vegetarians and ovo-lacto-vegetarians found raised MMA in 63% of subjects (>271 nmol/L), lowered holoTC concentrations (<35 pmol/L) in 73% , and hyperhomocysteinemia (>12 μmol/L) in 33%. In vegans, raised MMA was found in 86%, lowered holoTC in 90%, and hyperhomocysteinemia in 55% (4).
Persons with an increased vitamin requirement are a further risk group for B 12 deficiency-for example, pregnant and breast feeding women, patients with autoimmune disorders, or persons with HIV infection. Persons who regularly take proton pump inhibitors can also develop vitamin B 12 deficiency. B 12 deficiency is also widespread in patients with renal disorders (20) . In spite of normal plasma concentrations of vitamin B 12 or holoTC, these patients often have raised serum concentrations of MMA and homocysteine (20) . These can be corrected with vitamin B 12 substitution, which indicates a deficiency before starting treatment (20) . The likely cause is a disrupted cellular absorption of holoTC, which results in intracellular vitamin B 12 deficiency and raised metabolites. Studies have shown that patients with renal disorders may have higher concentrations of holoTC, which seems to contradict B 12 deficiency (20, 21) . This can be explained with the role of the kidney in transcobalamin filtration and resultant secondary accumulation of holoTC. The plasma concentration of holoTC in such (4, 22) . In randomized studies in elderly patients, a daily intake of 1 to 2 mg cyanocobalamin have resulted in normalization of the metabolic signs of the B 12 deficiency and in improved neurological symptoms-e.g., in terms of memory power, gait, perception of vibrations, and paresthesias (6, 17) . Vidal-Alaball et al. (23) have shown in randomized studies that compared with intramuscular application, high oral dosages of vitamin B 12 (1 mg and 2 mg; daily at the start of treatment, then weekly, and later monthly) are of comparable efficacy in terms of improved hematological and neurological symptoms.
The therapeutic recommendations with regard to dosage and administration of B 12 substitution treatment are divergent (24) . In the United States, patients usually receive vitamin B 12 injections of 1 mg daily in their first week of treatment. In the following month, they receive weekly injections and then monthly injections (25) . In Denmark, patients receive injections of 1 mg cyanocobalamin weekly during the first month and every 3 months subsequently, or 1 mg hydroxycobalamin every other month (e11).
The optimal dose of B 12 can be adjusted by testing B 12 status in blood by means of laboratory parameters. Measuring homocysteine and MMA concentrations is helpful in monitoring vitamin therapy (17) . The homocysteine concentration provides information on whether the intracellular methionine cycle is functioning (which depends on B vitamins), whereas MMA documents specifically the effectiveness of B 12 
